TRIMODAL ELECTRODE SYSTEM FOR PALLIDOTOMY & THALAMOTOMY

在医学上出现了几个有希望的报告之后 文献报道，苍白球切开术和丘脑切开术治疗青光眼 帕金森氏病相关的运动障碍 在过去的几年里一直在稳步增长。这些领域的复兴 有两种外科技术可以部分归因于 更可靠的微损伤系统和更准确的脑图 技巧。我们的目标是开发一种单一的颅内微电极 将包括三个关键组成部分的系统：1.)三模式(即， 记录、刺激、损伤)涂覆生物相容性的微电极 绝缘材料，2。)适当的电子设备，用于控制 3.三峰微电极)微定位元件。通过组合 具有生物兼容性的记录、刺激和损伤功能 技术和材料，三模微电极将访问靶标 对健康组织损伤较小的脑区。微电极功能 通过将每种模式集成到单个控制模块中来简化。 该系统将包括定制设计的微型定位器。这种方法 将提供目前无法提供的安全和准确程度 简化外科标测计算并将组件降至最低 切换错误。在单个包中提供所有这些功能将 使其定价非常有竞争力，并使其临床应用更多 性价比高。 建议的商业应用： 最近，苍白球切开术和丘脑切开术再次成为有效的治疗手段。 帕金森氏病相关运动障碍的治疗。它是 估计有35万美国人可能会从这些程序中受益。这个 一种高性能集成化颅内电极系统的研制 比目前的技术更准确和更容易使用的技术具有很好的商业价值 在这一亚群帕金森病患者中的治疗潜力。我们的目标是 生产一种价格适中的系统，对健康组织的损害较小 并缩短了程序的持续时间，从而减少了 减少并发症，减少手术和术后护理费用。

Following the appearance of several promising reports in the medical literature, the use of pallidotomy and thalamotomy for the treatment of Parkinson's Disease-related movement disorders has been steadily increasing over the past few years. The resurgence in these two surgical techniques can be attributed in part to the development of more reliable microlesioning systems and more accurate brain mapping techniques. Our goal is to develop a single intracranial microelectrode system that will incorporate three key components: 1.) a trimodal (i.e., recording, stimulation, lesion) microelectrode coated with biocompatible insulating materials, 2.) appropriate electronics for the control of the trimodal microelectrode, and 3.) micropositioning elements. By combining recording, stimulation and lesioning functions with biocompatible technology and materials, the trimodal microelectrode will access target brain areas with less damage to healthy tissue. Microelectrode function will be simplified by integrating each mode into a single control module. The system will Include custom-designed micropositioners. This approach will provide a degree of safety and accuracy not currently available by simplifying surgical mapping calculations and minimizing component switching error. Offering all these features in a single package will allow its pricing to be very competitive and make its clinical use more cost effective. PROPOSED COMMERCIAL APPLICATION: Recently pallidotomy and thalamotomy have reemerged as effective treatments of Parkinson's Disease-related movement disorders. It is estimated that 350,000 Americans may benefit from these procedures. The development of an integrated intracranial electrode system that is highly accurate and easier to use than current technologies has great commercial potential for treatment in this subpopulation of PD sufferers. Our goal is to produce a moderately-priced system that will damage less healthy tissue and shorten the duration of the procedures, resulting in fewer complications and reducing surgical and post-operative care costs.